Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.
Therapeutic Advances In Medical Oncology
Riedl, Jakob M JM; Hasenleithner, Samantha O SO; Pregartner, Gudrun G; Scheipner, Lukas L; Posch, Florian F; Groller, Karin K; Kashofer, Karl K; Jahn, Stephan W SW; Bauernhofer, Thomas T; Pichler, Martin M; Stöger, Herbert H; Berghold, Andrea A; Hoefler, Gerald G; Speicher, Michael R MR; Heitzer, Ellen E; Gerger, Armin A